DDInter1789 DDInter1747
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Thalidomide {u} (Compound) treats {v} (Disease) hematologic cancer
Thalidomide {u} (Compound) binds {v} (Gene) FGFR2
Thalidomide {u} (Compound) upregulates {v} (Gene) TGFBR2
Thalidomide {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Immunologically Active Molecule Activity
Thalidomide {u} (Compound) downregulates {v} (Gene) ARNT2
Thalidomide {u} (Compound) causes {v} (Side Effect) Myocardial ischaemia
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clarithromycin
Thalidomide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Astemizole
Thalidomide {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Thalidomide (Compound) resembles Lenalidomide (Compound)
Thalidomide (Compound) treats hematologic cancer (Disease)
Thalidomide (Compound) binds FGFR2 (Gene)
Thalidomide (Compound) upregulates TGFBR2 (Gene)
Thalidomide (Compound) is included by Decreased Immunologically Active Molecule Activity (Pharmacologic Class)
Thalidomide (Compound) downregulates ARNT2 (Gene)
Thalidomide (Compound) causes Myocardial ischaemia (Side Effect)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Astemizole
Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine